Confirms proposed Phase 3 development pathway and identifies new life cycle management targets for XF-73 Nasal
Brighton, United Kingdom – 6 July 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections, recently held a meeting with its Scientific Advisory Board and a number of international experts from the UK and US focused on the XF-73 Nasal development programme.
The panel of surgeons and infectious disease experts concluded that:
- The proposed XF-73 Nasal programme, consisting of two placebo-controlled surgical Phase 3 studies with a clinical endpoint, designed around FDA input, reflects the utility of XF-73 Nasal in all surgeries.
- The rapid antimicrobial action of XF-73 Nasal gives greater flexibility in the scheduling of surgeries than existing offerings and provides direct value to patients and institutions.
- Antimicrobial resistance remains of global importance, with S. aureus and resistant strains such as MRSA and MupRSA of great concern clinically. XF-73 Nasal, through its unique and rapid mechanism of action, can play an important role in antibiotic stewardship by reducing the need for post-op systemic antibiotics. Additionally, XF-73 Nasal could prevent horizontal transmission of S. aureus, thus further contributing to good antibiotic stewardship.
- New potential life cycle management indications are available for Destiny to explore, particularly in children (and their families), where there are concerns over the use of mupirocin and antiseptic approaches and a high unmet medical need remains.